Rhenovia team is multi-disciplinary with world experts in neuroscience, computational neurobiology, informatics, mathematics, physics, chemistry and pharmaceutical drug discovery. Team members combine over 100 years of cumulated professional experience and over 800 peer-reviewed publications, and many of them have known and work with each other for over thirty years.
Dr. Serge Bischoff, Co-Founder, President and CEO Neuropharmacologist, former Head of Research Programs in the Nervous System Department, Novartis, 30 years experience leading drug discovery programs in CNS; trained in executive management, leadership and business development (see full career biosketch in 'Publications').
Pr. Michel Baudry, Co-Founder, VP CSO Senior Scientific Director. Currently Professor of Biomedical Sciences and Dean of the Graduate College of Biomedical Sciences at Western University of Health Sciences in Pomona, CA. Dr. Baudry is one of the 100 most cited neuroscientists and a world expert in the field of learning & memory (see full career biosketch in 'Publications').
Michel Faupel, Co-Founder, VP COO. Director of the Headquarters of Rhenovia, Director for New Technologies and Opportunities. Former Life Sciences Chemist, 38 years experience in BioMedical Research at Novartis Institutes for BioMedical Research Basel. Excecutive staff member, (Syst.Biology, Genomics and Proteomics). Michel Faupel serves also as Associate Professor at the University of Haute Alsace / Biotech Engineering. See full career biosketch in 'Publications'.
Dr. Florian George, Director CFO, Global Contract Manager, Chemist, entrepreneurs, expert in the financing of innovation, trained in contract management, finances and intellectual property.
Pr. Jan Kremers, Co-Founder, VP Director Eye Pathologies In charge of the business development in Austria, Germany, Switzerland and the Netherlands.
Neurobiologist, expert in eye physiology, currently Dr. Kremers is Professor of Experimental Ophthalmology at the Department of Ophthalmology of the University of Erlangen-Nuremberg, Germany (see full career biosketch in 'Publications').
Dr. Jean-Marie Bouteiller, Director of the Biosimulation Platforms Computational Neurobiologist and informatics engineer, is with Ted Berger, the inventor of the first proprietary modeling and simulation platform. He is currently post-doctoral fellow at the Center for Neural Engineering of University of Southern California, Los Angeles.
Jacques Baudry,Co-Founder, Company Manager, Engineer, Head of Rhenovia's financing commission.
Peter Stark, CEO of Portmann Instruments, Switzerland. Partner in the Development of Technologies, also in charge of the deployment of Rhenovia in Switzerland.
Dr. Saliha Moussaoui, Neurobiologist, Director of the Operational Team, Director of the Applications of Biosimulation to Drug Discovery & Development.
Marc Loizeau, Experienced entrepreneur, and member of investor funds. Advisor for the Communication Strategy and Press Relationship.
Prof. Ted Berger, Neurobiologist, pioneer in computational neurosciences and neuronal prostethis. Chairman of Rhenovia Scientific Council.
Rhenovia Supervisory Board - Shareholders
Dr. Serge Bischoff, President
Dr. Robert Zimmer
Peter Starck, Secretary
Rhenovia Advisory Board
Scientific, Technologies, Business Development, Finances, Legal and Regulations
Dr. Bernard Malfroy Camine
Dr. Dalia Cohen
Dr. Daniel van Kammen
Dr. Bernard Scatton
Dr. Graeme Bilbe
Dr. Georges Haas
Prof. Ted Berger
Dr. Serge Braun
Prof. Pierre Braunstein
Dr. James Koenig
Dr. Hans Allgeier
Prof. Henry Markram
Prof. Jean-Louis Reymond
Dr. Theodore (Ted) Berger, Chairman Dr. Theodore Berger, David Packard Professor, Departments of Biomedical Engineering and Biology (Neurobiology), Director of the Center for Neural Engineering, University of Southern California, Los Angeles. He is a World expert in non-linear analysis of neural networks and in development of neural prostheses. Dr. Berger received his Ph.D. from Harvard University in 1976, joined the Departments of Psychiatry and Neuroscience at the University of Pittsburgh in 1979, where he became full professor in 1987. Since 1992 he has been professor of biomedical engineering and neurobiology at the University of Southern California. Dr. Berger became Director of the Center for Neural Engineering in 1997. He has published over 170 journal articles and book chapters, and is co-editor of a book published by MIT Press on Toward Replacement Parts for the Brain: Implantable Biomimetic Electronics as Neural Prostheses. Dr. Berger currently is chairing a world-wide study of brain-computer interfaces that is being funded by multiple agencies of the NSF, NIH, and DoD.
Dr.Henry Markram, Project Director of the Blue Brain Project, Director of the Center for Neuroscience & Technology and co-Director of EPFL's Brain Mind Institute, obtained his B.Sc. (Hons) from Cape Town University, South Africa under the supervision of Rodney Douglas and his Ph.D from the Weizmann Institute of Science, Israel, under the supervision of Menahem Segal. During his PhD he discovered a link between acetylcholine and memory mechanisms by showing that acetylcholine modulates the primary receptor linked to synaptic plasticity. In 2002 he moved to EPFL as full professor and founder/director of the Brain Mind Institute and Director of the Center for Neuroscience and Technology. At the BMI, in the Laboratory for Neural Microcircuitry, Markram has continued to unravel the blueprint of the neocortical column, building state-of-the-art tools to carry out multi-neuron patch clamp recordings combined with laser and electrical stimulation as well as multi-site electrical recording ,chemical imaging and gene expression. Markram has received numerous awards and published over 75 papers.
Dr. Pierre Braunstein Dr. Pierre Braunstein is a former major of the Ecole Nationale Supérieure de Chimie of Mulhouse, and is presently exceptional class Director of Research at the CNRS, Head of the Laboratory of Coordination Chemistry at the University Louis Pasteur of Strasbourg. He is member of several prestigious Academies, including the French Academy of Sciences, the European Academy of Sciences (2002), the German Academy of Life Science Research Leopoldina (2005) and corresponding member of the Academy of Sciences of Saragosse. Dr. Braunstein is also Fellow de la Royal Society of Chemistry (1996) and of the Japanese Society for the Promotion of Science (1997).
Dr. Serge Braun
Scientific Director of AFM, the French Neuromuscular diseases Association. He has 10 years of experience in the University and 10 years in the biotechnology domain. He obtained his degree in Pharmacy and a PhD in Pharmacology from the University of Strasbourg, France. Dr. Braun joined from 1990-1992 as postdoctoral fellow the neuromuscular Center School of Medicine of the University of Southern California in Los Angeles, USA. From 1992 to 1995, he returned as Research assistant to the School of Pharmacy of Strasbourg working on the pathogenesis and treatment of different genetic and acquired neuromuscular diseases. In 1995 he joined Transgene (Strasbourg) where he became Scientific Director and developed his career in the field of gene therapy, gene diseases and of immunotherapy cancer. He was co-founder of Neurofit a contract research organization specialized in preclinical testing of both the central and the peripheral nervous system. He was vice President of Alsace BioValley, the tri-national initiative, non-profit organization, for the development of a major biotech cluster in Europe He is also scientific expert of different government institutions, non-profit organization, VC's funds and reviewer of major journals.
Me Ludovic Doutreleau, business lawyer
Numa Rengot, legal affairs
Jean-Marc Krieger, commisssaire aux comptes
Thierry Blind, expert accountant
Board of Consultants
Dr. Hans Allgeier, medicinal chemist
Dr. Jean-Louis Reymond, prof chemistry, chemoinformatics
Dr. James Koenig, prof psychiatry, neuroendocrinologist
Dr. Georges Haas, Chemist, ex.Global Head of Research and preclinical Development,Ciba Geigy, Basel, Switzerland